Status:

COMPLETED

Impact of Aggressive Versus Standard Drainage Regimen Using a Long Term Indwelling Pleural Catheter

Lead Sponsor:

Duke University

Collaborating Sponsors:

C. R. Bard

Conditions:

Pleural Effusion, Malignant

Eligibility:

All Genders

19+ years

Phase:

PHASE4

Brief Summary

Purpose and Objective: The purpose of this study is to determine if the rate of spontaneous pleurodesis using the Pleurx® catheter could be increased by simply increasing the frequency of pleural drai...

Detailed Description

Study Population: Patients greater than 18 years of age with malignant pleural effusions will be identified and approached in clinic by the Principle and Co-Investigator. Informed consent will be obta...

Eligibility Criteria

Inclusion

  • Age greater than 18 years old
  • Pleural effusion (etiology fulfilling one of the following criteria):
  • Malignant effusion confirmed by cytology or pleural biopsy
  • Exudative effusion in the setting of known malignancy with no other identifiable cause
  • Malignant effusion due to tumors that are historically rapidly responsive to systemic therapy (small cell lung cancer, hematological malignancies) will only be included if refractory to standard chemotherapy
  • Symptoms such as shortness of breath, cough, or chest fullness/chest discomfort
  • Age greater than 18 years old
  • Pleural effusion (etiology fulfilling one of the following criteria):
  • Demonstration of symptomatic improvement after therapeutic thoracentesis (removal of ≤ 1.5 L of pleural fluid)
  • Recurrent pleural effusion after therapeutic thoracentesis

Exclusion

  • Projected life expectancy less than 30 days as predicted by Karnofsky Performance Status score less than 30
  • Radiographic evidence of trapped lung - persistent lung collapse with failure of the lung to reexpand following drainage of a pleural effusion
  • Radiographic evidence of loculated pleural fluid
  • Previous attempted pleurodesis on the affected side
  • Previous lobectomy or pneumonectomy on the affected side
  • Patient receiving intrapleural chemotherapy
  • Chylothorax - pleural effusion with triglyceride levels \> 110 mg/dl or chylomicrons on lipoprotein analysis, most commonly due to trauma/obstruction of the thoracic duct
  • Parapneumonic effusion - pleural effusion associated with pneumonia
  • Empyema - infected pleural space as defined by purulent pleural fluid, positive gram stain, or positive culture
  • Inability to adequately perform pleural drainage at home
  • Uncorrectable bleeding disorder
  • Skin infection at the site of intended catheter insertion
  • Pregnancy

Key Trial Info

Start Date :

August 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2013

Estimated Enrollment :

150 Patients enrolled

Trial Details

Trial ID

NCT00978939

Start Date

August 1 2009

End Date

October 1 2013

Last Update

December 30 2013

Active Locations (6)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (6 locations)

1

National Jewish Medical Center

Denver, Colorado, United States, 80206

2

Johns Hopkins University

Baltimore, Maryland, United States, 21287

3

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States, 02215

4

Lahey Clinic

Burlington, Massachusetts, United States, 01805